Prescribing Doc's Testimony Key In 2nd Philly Xarelto Trial

By Matt Fair (April 4, 2018, 5:47 PM EDT) -- After a $28 million verdict in a bellwether Xarelto case in Philadelphia was axed over testimony that additional warnings about the drug's bleeding risks wouldn't have changed a doctor's prescribing decision, attorneys say the plaintiff in a second trial set to begin Thursday will face a challenge ensuring similar testimony doesn't derail his case.

Judge Michael Erdos threw out the $28 million verdict, the first that plaintiffs have managed to win across four Xarelto-related product liability trials in state and federal court against a pair of Bayer AG and Johnson & Johnson units, in January based on testimony from a prescribing...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!